These data suggest a novel pathway by which AQP5 influences bronchoconstriction. This observation is of special interest because studies to identify genetic loci involved in airway hyperresponsiveness associated with asthma bracket genetic intervals on human chromosome 12q and mouse chromosome 15, which contain the Aqp5 gene.
Aquaporin 5 (AQP5) is a mercurysensitive water channel expressed in mouse salivary gland acinar cells, alveolar type I cells, lacrimal glands, and the eye (1-3). However, the function of AQP5 in mouse lung physiology and pathophysiology is largely unknown. Recent studies have explored the regulation of Aqp5 gene expression in normal and disease states. In a mouse model of acute lung injury, AQP5 mRNA and protein expression were significantly decreased in association with pulmonary inflammation and edema resulting from adenoviral infection (4) . Moreover, AQP5 expression in a murine lung epithelial cell line (MLE12) is modulated by the proinflammatory cytokine TNFα through an nuclear factor (NF)κBdependent pathway (5) . Keratinocyte growth factor also has been shown to mediate the differentiation status of alveolar epithelial cells and AQP5 expression (6) . However, a clear understanding of AQP5 function in the lung remains to be discerned.
Previously published studies have addressed functional questions limited to the examination of the role of AQP5 in type I cells in fluid clearance and airspacecapillary osmotic water permeability. Of significance, isolated perfused lungs from Aqp5 mice were shown to have a 10fold reduction in airspacecapillary osmotic water permeability (7) . Experiments addressing the role of AQP5 in alveolar fluid clearance failed to indicate a role for AQP5 in this process under certain physiological conditions (8) . Based on the results of these studies, some have concluded that AQP5 does not play a major role in lung physiology. Contrary to these conclusions, the data reported here clearly define a novel function for AQP5 in lung physiology.
In this report, we have examined the expression pattern of AQP5 in the lung and have shown that, in addition to expression in alveolar type I cells, AQP5 is also detected in alveolar type II cells and tracheal and bronchial epithelium in mice. By using Aqp5 mice, we have directly assessed AQP5 function in the lung by using histological and physiological analyses. Our results show a novel role for AQP5 in airway responsiveness. Interestingly, previously reported genetic linkage studies identify syntenic regions of mouse chromosome 15 (9) and human chromosome 12q (10, 11) , in which Aqp5 resides (12, 13) , as containing loci linked with hyperreactivity to bronchoconstriction. This genetic evidence supports the physiological results presented here, which implicate AQP5 in the pathogenesis of bronchial hyperreactivity.
METHODS
Aqp5-Deficient Mice. Mice null for Aqp5 were generated as described (14) . Mice were bred and housed in a pathogenfree environment. to detect the antigen:antibody complexes. Briefly, inflationfixed lungs were washed in PBS and paraffin embedded. Paraffinembedded lungs were section at 5 μm and deparaffinized in HemoDe (Fisher Scientific), followed by ethanol rehydration. labeling. Subsequent processing, embedding, sectioning, and labeling procedures were carried out as previously described (15) . Sections were examined and photographed at 60 kV in a Philips CM10 TEM.
Wet-to-Dry Weight Ratios. Wettodry weight ratios were determined for lung tissue excised from Aqp5 and Aqp5 mice (n = 8 each group) as described (4).
Gas Exchange. Lung CO exchange was analyzed in anesthetized, mechanically ventilated Aqp5 and Aqp5 mice (n = 6 each group) as described (16) . Mice were first ventilated with 95% O /5% CO for 10 min, and two 40μl arterial blood samples were taken via a carotid catheter to establish a baseline. Mice were then ventilated with 100% O , and arterial blood samples were taken at 30 s, 3 min, 6
min, and 9 min under this condition. Arterial pCO , pO , and pH were analyzed by using a Chiron (Norwood, MA) blood gas analyzer (model 384).
Resistance and Compliance Measurements. Pulmonary responsiveness to bronchoconstrictor agents was determined by measuring airway pressure and flow in anesthetized, ventilated Aqp5 and Aqp5 mice (n = 6 each group) according to a published method (17) . Briefly, anesthetized mice were tracheostomized by using a custom built cannula with ports for inspiration and expiration, and for monitoring airway pressure and airway flow. The femoral artery and vein were cannulated for continuous monitoring of blood pressure and the i.v.
administration of drugs. Ventilation and data collection and analysis were accomplished by using a custom written software program (Mouse Reactivity System, U.S. Environmental Protection Agency, Research Triangle Park, NC), which uses flow and pressure signals to calculate total lung resistance (R ) and dynamic compliance (C ). In addition, the airway pressuretime index (APTI) was calculated by integrating the change in peak airway pressure for the 2min period after administration of each challenge dose, as previously described (18) . Mice were ventilated at a rate of 150 breaths per minute and a tidal volume of ≈200 μl. Values from each breathing cycle were averaged over 2s intervals and saved to a data file. After establishing a baseline, mice were challenged with increasing doses of Ach administered i.v. via a jugular catheter (1-1,000 ng/g body weight, delivered in a 10 μl bolus of saline). Four to eight minutes were allowed between doses to permit a return to baseline values.
Whole Animal Barometric Plethysmography. Airway responsiveness to methacholine was determined in awake, unrestrained Aqp5 and Aqp5 mice (n = 6 each group) by using barometric plethysmography to measure enhanced pause (Penh), a unitless measure that has been shown to correlate with the changes in airway resistance that occur during bronchial challenge with methacholine (19) . Mice were equilibrated in the plethysmography chamber for 10 min before challenge. By using a previously reported protocol (20), mice were challenged with increasing doses of methacholine (2.5 mg/ml to 80 mg/ml) after baseline Penh was first established with aerosolized PBS.
Each dose was delivered over 1 min, and Penh was recorded continuously for 4 min afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software.
Tracheal Smooth Muscle Contraction. Isometric force measurements of tracheal smooth muscle contractility were determined in isolated tracheal ring preparations from Aqp5 and Aqp5 mice (n = 6 each group) as described (21) . Cumulative concentration force relationships to Ach (10 -10 M), and relaxation to isoproterenol (10 -10 M), after a precontraction with 10 M Ach. Epithelial dependent relaxation to substance P (10 M) or ATP (10 M) also were assessed.
Surfactant Protein B (SP-B) ELISA. SPB concentrations were determined from bronchoalveolar lavage or total lung homogenates from Aqp5 and Aqp5 mice (n = 6 each group) as described (22) . SPB concentration was expressed as ng/ml of bronchoalveolar lavage fluid and as ng SPB/mg protein. Values represent the mean value ± SE.
RESULTS
AQP5 Expression in Mouse Lung. By using immunohistochemical staining and light microscopy, AQP5 expression was previously reported in alveolar Type I cells of the mouse lung (2), and in rat distal lung, perihilar region of the conducting airway, and nasopharynx (1, 3) . In humans, in situ hybridization and immunofluorescence were previously used to detect AQP5 expression in the apical membrane of columnar cells of the superficial epithelium and submucosal gland acinar cells of nose and bronchial epithelia, and alveolar Type I cells (23) . Our data show that, in addition to alveolar Type I cell expression, immunohistochemical staining of lung sections from Aqp5 mice showed AQP5 immunoreactivity in epithelial cells of the trachea, main stem bronchi, and extrapulmonary lobar bronchioles, but not in the bronchiolar epithelium of the more distal, intrapulmonary bronchioles (Fig. 1) . In the trachea, immunopositive staining for AQP5 was detected at the apical, basal, and basallateral surfaces of both secretory and ciliated epithelial cells ( Fig. 1 A and B) . In the main stem bronchi, immunopositive staining was detected in cells located along the basal aspect of the bronchial epithelium, as well as along the luminal surface in association with ciliated cells (Fig. 1 C and D) . In the perihilar region of the lobar bronchioles, immunopositive staining was restricted to cells located along the basal aspect of the epithelium ( Fig. 1 E and F) . Although no immunostaining was detected in the intrapulmonary bronchioles, staining was detected along the apical, or luminal, surface of the alveolar epithelium ( Immunogold labeling of thin sections of the distal lung with antiAQP5 antibodies revealed expression of AQP5 in alveolar type I (Fig. 2 A and B) and alveolar type II cells (Fig. 2 D and E) . In type I cells, gold particles were associated with both the apical and basal cell membranes. In type II cells, labeling of the microvilli on the apical cell membrane was most prominent. No immunospecific staining was observed in lungs from Aqp5 mice (Fig. 2C) . Wet-to-Dry Weight. In addition to microscopic evaluation, wettodry weight ratios were used to assess potential pulmonary edema and/or fluid imbalance in lungs from Aqp5 null mice (data not shown). No significant difference was observed between the two genotypes, suggesting that, under normal physiological conditions, AQP5 deficiency does not cause pulmonary edema.
Gas Exchange. Because AQP5 is expressed in the alveolar epithelium at the site of gas exchange, Aqp5 and Aqp5 mice were analyzed for the ability to transport gases via arterial blood exchange. Arterial blood O , CO , and pH were assessed under conditions of 95% O /5% CO , and at 30 s, 3 min, 6 min, and 9 min after a switch to 100% O . No significant differences were observed between the two genotypes (data not shown), suggesting that, under normal conditions, AQP5 deficiency does not result in an altered ability to effectively exchange gases. Airway Responsiveness. AQP5 expression in the conducting airways suggests a role for AQP5 in regulating pulmonary mechanics. Airway reactivity was evaluated by measuring total lung resistance (R ) and dynamic compliance (C ), as well as the APTI in anesthetized, ventilated mice (Fig. 3 A-C) . Aqp5 mice were found to be hyperreactive to intravenously administered ACh (Fig. 3 A-C) as compared with wildtype littermates. Although there were no differences in the baseline measurements of R and C between the two groups of animals, the magnitude of the responses of both variables to increasing doses of ACh was increased in Aqp5 mice compared with Aqp5 mice (P < 0.05). Furthermore, the APTI response to ACh, which is a measure of not only the peak magnitude but also the duration of the constrictor response, was markedly increased in the Aqp5 mice. Whole body barometric plethysmography was used to determine whether hyperreactivity to bronchoconstriction could be induced via inhalation of methacholine in awake, unrestrained, spontaneously breathing Aqp5 null mice. In this method, the enhanced pause (Penh) was used as a measure of bronchoconstriction (see Methods). Consistent with the resistance and compliance results compiled by using
ACh as an agonist, Aqp5 mice were hyperreactive to bronchoconstriction by inhaled methacholine in a dosagedependent fashion (Fig.   4 ). Thus, AQP5 deficiency results in airway hyperreactivity to bronchoconstriction with cholinergic stimulation, independent of the route of administration. 
Surfactant Protein-B (SP-B)
. SPB is a 79aa polypeptide expressed in alveolar type II cells that interacts with phospholipids to enhance the surface tension of the alveolus in the lung (24) . Deficiency in SPB has been shown to affect lung function, and results in reduced lung compliance (25) . SPB concentrations were analyzed from total lung homogenates and bronchoalveolar lavages from Aqp5 and Aqp5 mice. No significant differences were observed in SPB concentrations obtained from lung homogenates (Aqp5 : 15.4 ± 1.46 ng SP B/mg protein; Aqp5 : 14.6 ± 1.42 ng SPB/mg protein) or from lung lavages (Aqp5 : 262 ± 25.7 ng SPB/ml lavage fluid; Aqp5 : 264 ± 25.01 ng SPB/ml lavage fluid), suggesting that AQP5 deficiency did not result in altered SPB concentration. 
DISCUSSION
The role of AQP5 in the regulation of lung fluid homeostasis and its potential contribution to lung function is largely unknown. In this study, we examined the expression pattern of AQP5 in mouse lung, and analyzed parameters of lung function in Aqp5 mice. The results presented here implicate a novel physiological role for AQP5 in cholinergicstimulated bronchoconstriction.
Immunohistochemical analyses showed that AQP5 expression in mouse lung was not limited to type I cells, but was also detected in alveolar type II cells. Alveolar type II cells also express the epithelial sodium channel (ENaC), important in the transport of sodium across the alveolar epithelium (26, 27) . Because water movement through AQPs is driven by osmotic gradients that are generated by sodium gradients, the coexpression of AQP5 and ENaC in alveolar type II cells may reflect coregulation of sodium and water transport in the alveolar region.
Physiological examination of Aqp5 mice by using resistance and compliance measurements and barometric whole body plethysmography showed that Aqp5 mice are hyperresponsive to bronchoconstriction by cholinergic stimulation. Our data suggest that the observed altered reactivity is not due to altered SPB concentration. Thus, the mechanism of AQP5mediated responsiveness is not likely to result in changes in surfactantcontrolled surface tension. Other parameters of normal lung function were not affected by AQP5
deficiency. The absence of AQP5 expression did not affect gas exchange nor did it result in pulmonary edema under normal physiological conditions.
Identification of AQP5 expression in bronchial epithelial cells strongly implicates AQP5 as the previously described, but unidentified mercurysensitive water channel responsible for mediating osmotically driven transcellular water flow and airway surface liquid composition (28, 29) . It has been shown that a local increase in the osmolarity of the airway surface liquid as a result of respiratory water loss or inhalation of hypertonic saline induces bronchoconstriction in asthmatic patients (30, 31) . Because bronchial epithelium has both metabolic and secretory functions that mediate both the release of bronchodilators and removal of bronchoconstricting agents (32) (33) (34) , it is possible that the absence of AQP5 at the luminal surface of tracheal and bronchial epithelial cells leads to altered extracellular ionic composition that could affect the release and/or clearance of bronchoreactive substances, resulting in rapid airway responses. The lack of statistically significant alterations in smooth muscle contractility of trachea rings from Aqp5 and Aqp5 mice may be due to the fact that the immersion of the tracheal rings in a wellstirred PBS bath prevents changes in the local extracellular space. Alternatively, an
AQP5sensitive neural signaling pathway between the epithelium and smooth muscle may be disrupted in isolated tracheal ring preparations. Future studies by using methods that do not disrupt the integrity of the tracheal smooth muscle microenvironment will be needed to fully elucidate the mechanism responsible for the observed hyperreactivity.
Although our data clearly demonstrate a role for AQP5 in cholinergicstimulated bronchoconstriction in mice, a "direct" role for AQP5 in this process has not yet been elucidated. Our data do not exclude the possibility that AQP5 ablation results in the aberrant expression of other developmentally regulated or physiologically relevant genes whose function may provide a direct mechanism for the enhanced bronchoresponsivenss that we observe in the Aqp5 knockout mice. Additional analyses will be required to completely dissect the pathways involved in this AQP5dependent response.
Sensitivity of bronchial airway smooth muscle to constriction by muscarinic agonists such as Ach or methacholine characterize both asthma and chronic obstructive pulmonary disease (COPD) in humans (33) , pulmonary disorders that often are treated clinically with anticholinergic therapy (35, 36) . Although the mechanism of its involvement is not known, these results indicate AQP5 involvement in a novel mechanism of bronchoconstriction.
Several genetic linkage studies have been conducted in both humans and mice to map the trait of airway hyperresponsiveness in asthma susceptibility. Of relevance to this report is a mouse quantitative trait locus (QTL) genetic mapping study performed by De Sanctis and colleagues (9) . Airway hyperresponsiveness was mapped to mouse chromosome 15 (9) in the same region as the Aqp5 gene locus (12) .
Two studies have mapped major asthmasusceptibility loci on human chromosome 12q (10, 11) , the chromosomal location of human Aqp5 gene (12) . Human chromosome 12q and mouse chromosome 15 are syntenic within this region, which contains an aquaporin gene cluster (12, 13) . None of the above linkage reports identify Aqp5 as a candidate gene locus for asthma or bronchial hyperreactivity. 
